AI
| Followers | 843 |
| Posts | 122982 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Saturday, April 23, 2011 5:42:24 PM
ABT’s 1Q11 sales in emerging markets grew 38% year-over-year:
The 38% figure is somewhat artificial insofar as 2010 sales (but not 2009 sales) include the Solvay (#msg-41922225) and Piramal (#msg-50436738) acquisitions; however, even on an apples-to-apples basis, ABT’s 1Q11 sales in emerging markets grew more than 20% YoY.
Note the 117% growth in the Established Pharmaceuticals unit, which is where branded generics reside.
The 38% figure is somewhat artificial insofar as 2010 sales (but not 2009 sales) include the Solvay (#msg-41922225) and Piramal (#msg-50436738) acquisitions; however, even on an apples-to-apples basis, ABT’s 1Q11 sales in emerging markets grew more than 20% YoY.
Note the 117% growth in the Established Pharmaceuticals unit, which is where branded generics reside.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
